Andrew DillonRegulator

Biography

Sir Andrew Dillon CBE FMedSci was the founding chief executive of the National Institute for Health and Care Excellence (NICE), appointed in April 1999 when the organisation was established under Tony Blair's government, and retired in March 2020 after 21 years of service. Before NICE, he spent his career in NHS management, serving as general manager of the Royal Free Hospital (1986–1991) and chief executive of St George's Healthcare NHS Trust (1991–1999). Under his leadership, NICE became the world's most prominent health technology assessment body, developing evidence-based guidelines and cost-effectiveness appraisals covering medicines and treatments on the NHS in England, with influence extending to Wales and Northern Ireland. He was publicly known for challenging pharmaceutical companies on drug pricing and for championing transparent, evidence-based decision-making in health and care. Since leaving NICE, he has been a visiting professor at the Institute of Global Health Innovation at Imperial College London and works as an independent consultant. He was knighted in the New Year 2010 Honours for services to healthcare, and was elected a Fellow of the Academy of Medical Sciences in 2015.

References

1. 1.Sir Andrew Dillon to step down as NICE chief executive – Healthcare Leader News — Establishes tenure (April 1999–March 2020), founding role, NHS career background, and tributes on departure
2. 2.New Year 2010 Honours List – UK Government Transparency Data — Confirms knighthood awarded in New Year 2010 Honours for services to Healthcare, citing his role as Chief Executive of NICE
3. 3.After two decades taking on pharma over price, Sir Andrew Dillon steps down from NICE – Pharmaphorum — Establishes NICE's HTA role, Dillon's approach to pharmaceutical pricing, and NICE's coverage of England with influence over Wales and Northern Ireland
4. 4.NICE's long-serving chief exec Sir Andrew Dillon to step down – PMLiVE — Confirms knighthood year, NHS career start in 1975, and NICE's QALY cost-effectiveness methodology

Expertise

Cited on

• Hospital discharge / bed-blocking

Stated areas of expertise

• Health technology assessment
• Medicines pricing and cost-effectiveness
• NHS guidance and clinical guidelines
• Evidence-based healthcare policy
• Life sciences regulation
• NHS management

Notable achievements

• Founded and led NICE from its establishment in April 1999 until March 2020 — a tenure of 21 years as its only chief executive — during which NICE became a globally recognised health technology assessment body. Source ↗
• Knighted in the New Year 2010 Honours as 'Mr Andrew Patrick DILLON CBE, Chief Executive, National Institute for Health and Clinical Excellence, for services to Healthcare'. Source ↗
• Elected a Fellow of the Academy of Medical Sciences (FMedSci) in 2015. Source ↗
• After retirement from NICE, appointed Visiting Professor at the Institute of Global Health Innovation, Imperial College London. Source ↗
• In September 2013, wrote an open letter to The Times publicly challenging the pharmaceutical industry to justify the costs embedded in high drug prices presented to NICE for assessment. Source ↗

What they’ve said

• “Nice frequently flexes its baseline value-for-money threshold to facilitate access to promising new treatments.”

  Founding chief executive, National Institute for Health and Care Excellence, 1999-2020 · Hospital discharge / bed-blocking · 27 Aug 2026 · NHS drug pricing is all about the art of the deal | Letter ↗

Source references

1. NHS drug pricing is all about the art of the deal | Lettertheguardian.com · 27 Aug 2026

Contact & links

• Staff pagehttps://www.hsj.co.uk/andrew-dillon/1201391.bio
• Websitehttps://biotech-atelier.com/speakers/sir-andrew-dillon/
• Websitehttps://www.policyconnect.org.uk/people/sir-andrew-dillon

Organisational contact points only, each taken from a page the organisation publishes itself. No personal or direct contact details are held or shown.